🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Global Health Concern

The sexually transmitted infection are on the rise globally, with figures suggesting more than 82 million new cases annually. Especially elevated rates are seen in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the context of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the rise in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists anticipate that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This milestone marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Results and Global Access

Based on data detailed in a prominent scientific publication, the new drug successfully treated the vast majority of uncomplicated infections. This puts it on an equal footing with the typical regimen, which uses an injection and a pill. The trial involved over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians directly involved have shared positive views. The availability of a single-dose, oral treatment like this is described as a "critical tool" for gonorrhoea control. This is viewed as crucial to reduce the burden of the illness for people and to prevent the spread of untreatable gonorrhoea globally.